Sign in
NEUP Stock Price, Chart, Stats & News
Neuphoria Therapeutics Inc.
Save
Neuphoria Therapeutics Inc. (NEUP) does not currently pay a dividend.
14.94M
Market cap
–
Current P/E
–
Forward P/E
NEUP chart
Fundamentals
Gross margin | 94.74% |
Operating margin | -13728.73% |
Pretax margin | -10250.46% |
Net margin | -4546.55% |
Effective tax rate | 55.65% |
ROA | -1020.11% |
ROE | -1538.29% |
D/E | 0.00x |
Interest coverage ratio | – |
NEUP valuation
P/E | – |
P/S | 0.94x |
P/B | 0.63x |
P/CF | 0.25x |
P/FCF | 0.10x |
P/OCF | 0.25x |
PEG | -0.01x |
EV multiple | -0.04x |
About
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.
Similar securities
Based on sector and market capitalization
Report issue